Ocular Therapeutix

Company Description

Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company focused on eye care. The company leverages its ELUTYX bioresorbable hydrogel-based formulation technology for its commercial product DEXTENZA (for ocular inflammation and pain, and allergic conjunctivitis) and investigational product candidates AXPAXLI (for retinal disease) and PAXTRAVA (for open-angle glaucoma or ocular hypertension). The ELUTYX technology provides delivery solutions for therapies for various eye diseases including wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other conditions. In the last fiscal year, the company had a market cap of $1787 million, profits of $58 million, revenue of $64 million, and 274 employees.

Analysis

ANALYSIS: With an Obermatt 360° View of 4 (better than 4% compared with alternatives), overall professional sentiment and financial characteristics for the stock Ocular Therapeutix are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with all four indicators below average for Ocular Therapeutix. The consolidated Value Rank has a low rank of 14 which means that the share price of Ocular Therapeutix is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 86% of alternative stocks in the same industry. The consolidated Growth Rank also has a low rank of 37, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is lower than for 37% of competitors in the same industry. The consolidated Safety Rank has a riskier rank of 43, which means that the company has a riskier financing structure than 57% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a low rank of 12, which means that professional investors are more pessimistic about the stock than for 88% of alternative investment opportunities. ...read more

Country

USA

Industry Pharmaceuticals

Size Small

Website ocutx.com

Index

NASDAQ

Add to Watchlist

See Similar Stocks

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.